Sanara Medtech

SMTI · NASDAQ

$33.14+$0.00 (+0.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $33.14

SMTI analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 5 analysts

Average $35.70 (+7.7% upside)

Low: $35.35
Now: $33.14
High: $36.75

Upgrades and downgrades

The latest rating actions, newest first

SMTI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jul 30, 2026	Downgrade	Buy → Neutral	$36.00 → $35.00	40%
Freedom Broker	Jun 17, 2026	Initiates	Buy	$35.00	45%
Lake Street	Apr 15, 2026	Initiates	Buy	$32.00	36%
HC Wainwright & Co.	Jan 26, 2026	Maintains	Buy	$36.00	40%
HC Wainwright & Co.	Nov 14, 2025	Maintains	Buy	$54.00 → $36.00	40%

The case for and against

Updated May 5, 2026

Bull case

Sanara MedTech is a promising company, with strong growth potential and a solid financial standing. Its preliminary financial results for 2025 show 3-5% YoY revenue growth, which is expected to increase to 13-17% in 2026. Additionally, the company has a diverse product portfolio that includes soft tissue repair and bone fusion products, which are in high demand in the surgical market. Furthermore, Sanara has secured a new contract with a major group purchasing organization, and plans to launch a new bone bioadhesive in 2027, further expanding its product offerings. Despite a recent net loss, the company's continuing operations have become profitable and management is focused on sustaining revenue growth and improving profitability in the future. With an EV/Revenue multiple of 3.0x and projected revenue for the next 12 months, Sanara MedTech's stock has a price objective of $36, making it a potential buy for investors.

Bear case

Sanara MedTech is facing financial challenges as the company has a high level of long-term debt compared to its available cash and borrowing capacity. Additionally, the company's revenue growth may be impacted in the near future as their key product, BIASURGE, received a contract from Vizient Inc. which will not take effect until January 1, 2026. Furthermore, the company's cash flows from operating activities are low and may not be able to support their operations in the near-term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.